fda warning letters compounded semaglutide 2025 september Drug compounders sue over declaration ending Wegovy shortage Diabetes advocacy group discourages use
Description
Calling Shunnarah was the best decision I made
First, before PSM, baseline characteristics differed significantly between groups, which could have affected the outcome analysis
And before licensing, manufacturers would have to prove that the drug was not only absorbed reliably and consistently via patch, and that these products worked as well as the (proven) injectable versions
Share your thoughts and join the conversation in the comments
Consistency outweighs intensity: Long-term sustainable habits produce results that short-term interventions cannot
